March, 24
InSysBio announces its participation in Quantitative Systems Pharmacology Conference 2022 (QSPC2022) which is to be held on April 20-22, 2022, Leiden, The Netherlands. InSysBio team is going to present its QSP tools at the Booth and 15 posters in frames of the Conference, namely:
Affiliation: (1) InSysBio, Moscow, Russia, (2) Lomonosov Moscow State University, Moscow, Russia
See our latest posters: InSysBio team posters
About InSysBio
InSysBio is a Quantitative Systems Pharmacology (QSP) company located in Moscow, Russia (INSYSBIO LLC) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com.
← | November 2019 | → | ||||
Mo | Tu | We | Th | Fr | Sa | Su |
---|---|---|---|---|---|---|
1
|
2
|
3
| ||||
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
12
|
13
|
14
|
15
|
16
|
17
|
18
1.
18 Nov 2019 19:58
Course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics
This year InSysBio CEO Dr Oleg Demin with expert modelers Tatiana Karelina and Evgeny Metelkin and modelers Dmitry Shchelokov, Svetlana Rubina and Veronika Musatova are giving the course “Modeling for systems biology and biomedicine” at the Faculty of Bioengineering and Bioinformatics, Lomonosov Moscow State University.
|
19
|
20
|
21
|
22
|
23
|
24
|
25
1.
25 Nov 2019 18:47
PK/RO simulator for anti-PD-1 mAbs
InSysBio, a pioneer in Quantitative Systems Pharmacology (QSP), modeling and simulation for drug development, announced the launch of application ‘PK/RO simulator for anti-PD-1 mAbs’. The application is based on the model allowing to predict pharmacokinetics and target binding in human for therapeutic antibodies against PD-1 receptor.
|
26
|
27
|
28
|
29
|
30
|